JP2024532482A - 免疫活性を刺激するための方法および組成物 - Google Patents

免疫活性を刺激するための方法および組成物 Download PDF

Info

Publication number
JP2024532482A
JP2024532482A JP2024513926A JP2024513926A JP2024532482A JP 2024532482 A JP2024532482 A JP 2024532482A JP 2024513926 A JP2024513926 A JP 2024513926A JP 2024513926 A JP2024513926 A JP 2024513926A JP 2024532482 A JP2024532482 A JP 2024532482A
Authority
JP
Japan
Prior art keywords
antigen
receptor
seq
cell
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024513926A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023028657A5 (https=
JP2024532482A5 (https=
Inventor
シュリゲル，パトリック
ジョーチュナー，アレクサンダー
Original Assignee
バイオセプター （オースト） プロプライエタリー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021902832A external-priority patent/AU2021902832A0/en
Application filed by バイオセプター （オースト） プロプライエタリー・リミテッド filed Critical バイオセプター （オースト） プロプライエタリー・リミテッド
Publication of JP2024532482A publication Critical patent/JP2024532482A/ja
Publication of JPWO2023028657A5 publication Critical patent/JPWO2023028657A5/ja
Publication of JP2024532482A5 publication Critical patent/JP2024532482A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2024513926A 2021-09-01 2022-09-01 免疫活性を刺激するための方法および組成物 Pending JP2024532482A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2021902832A AU2021902832A0 (en) 2021-09-01 Methods and compositions for stimulating immune activity
AU2021902832 2021-09-01
PCT/AU2022/051070 WO2023028657A1 (en) 2021-09-01 2022-09-01 Methods and compositions for stimulating immune activity

Publications (3)

Publication Number Publication Date
JP2024532482A true JP2024532482A (ja) 2024-09-05
JPWO2023028657A5 JPWO2023028657A5 (https=) 2025-08-01
JP2024532482A5 JP2024532482A5 (https=) 2025-08-01

Family

ID=85410590

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024513926A Pending JP2024532482A (ja) 2021-09-01 2022-09-01 免疫活性を刺激するための方法および組成物
JP2024513973A Pending JP2024532489A (ja) 2021-09-01 2022-09-01 新規の機能不全ｐ２ｘ７結合剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024513973A Pending JP2024532489A (ja) 2021-09-01 2022-09-01 新規の機能不全ｐ２ｘ７結合剤

Country Status (8)

Country Link
US (2) US20240376193A1 (https=)
EP (2) EP4395814A4 (https=)
JP (2) JP2024532482A (https=)
CN (2) CN117813109A (https=)
AU (2) AU2022335932A1 (https=)
CA (2) CA3223086A1 (https=)
MX (2) MX2023015028A (https=)
WO (2) WO2023028657A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4400516A1 (en) * 2014-12-15 2024-07-17 The Regents of the University of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
CN119792512A (zh) * 2020-10-14 2025-04-11 维里迪安治疗公司 用于治疗甲状腺眼病的组合物和方法
TW202320850A (zh) 2021-08-10 2023-06-01 美商維里迪恩醫療股份有限公司 用於治療甲狀腺眼病之組合物、劑量及方法
JP2026507807A (ja) * 2023-03-08 2026-03-06 バイオセプター （オースト） プロプライエタリー・リミテッド 機能不全ｐ２ｘ７受容体に結合するためのキメラ抗原受容体
WO2024211413A2 (en) * 2023-04-05 2024-10-10 Arizona Board Of Regents On Behalf Of The University Of Arizona Trogocytosis in cancer cells and methods for treating cancer related thereto
WO2024220870A1 (en) * 2023-04-19 2024-10-24 The University Of Chicago Antibody-targeted enzymatic chemoprotection
AU2024269870A1 (en) * 2023-05-05 2025-11-20 Board Of Regents, The University Of Texas System Multi-receptor natural killer cells
AU2024306505A1 (en) * 2023-06-30 2025-10-16 Biosceptre (Aust) Pty Ltd Molecules and methods for activating car t cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2904911T3 (es) * 2009-08-20 2022-04-06 Biosceptre Aust Pty Ltd Anticuerpos anti-receptor P2X7 y fragmentos de los mismos
JP5992831B2 (ja) * 2009-12-24 2016-09-14 バイオセプター・（オーストラリア）・ピーティーワイ・リミテッド 非機能性オリゴマーｐ２ｘ７受容体に対する抗体
US20180037650A1 (en) * 2015-04-02 2018-02-08 Biosceptre (Uk) Limited Pain Treatment
EP3347474B1 (en) * 2015-09-11 2020-11-04 Biosceptre (UK) Limited Chimeric antigen receptors and uses thereof
CN109862883A (zh) * 2016-10-21 2019-06-07 生物权威（英国）有限公司 细胞毒性颗粒
EP3797164A4 (en) * 2018-05-21 2022-03-02 Biosceptre (Aust) Pty Ltd CHIMERIC ANTIGEN RECEPTORS WITH MODIFIED LINKER DOMAINS AND THEIR USES
JP7682797B2 (ja) * 2019-03-20 2025-05-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クローディン６二重特異性抗体
KR20210148228A (ko) * 2019-03-27 2021-12-07 내셔날 리서치 카운실 오브 캐나다 항-EGFRvIII 항체 및 그의 항원-결합 단편
JP2024510739A (ja) * 2021-03-11 2024-03-11 バイオセプター （オースト） プロプライエタリー・リミテッド 新規な細胞治療システム

Also Published As

Publication number Publication date
EP4395813A1 (en) 2024-07-10
WO2023028657A1 (en) 2023-03-09
AU2022341030A1 (en) 2023-11-30
EP4395814A1 (en) 2024-07-10
AU2022335932A1 (en) 2023-11-30
CA3223079A1 (en) 2023-03-09
CA3223086A1 (en) 2023-03-09
CN117881421A (zh) 2024-04-12
EP4395813A4 (en) 2025-07-09
US20240368282A1 (en) 2024-11-07
US20240376193A1 (en) 2024-11-14
EP4395814A4 (en) 2025-09-03
WO2023028653A1 (en) 2023-03-09
CN117813109A (zh) 2024-04-02
MX2023015469A (es) 2024-01-19
JP2024532489A (ja) 2024-09-05
MX2023015028A (es) 2024-02-16

Similar Documents

Publication Publication Date Title
US20240368282A1 (en) Methods and compositions for stimulating immune activity
US20240018251A1 (en) Bcma-targeting single-domain antibody and use thereof
JP2021534762A (ja) 抗メソテリンキメラ抗原受容体（ｃａｒ）構築物及びその使用
US20200062858A1 (en) Trispecific antigen binding proteins
US20250281611A1 (en) Novel cell therapy system
CA3030837A1 (en) Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
CA3032054A1 (en) Combination therapies of chimeric antigen receptors and pd-1 inhibitors
CN113784980B (zh) 人源化抗Claudin18.2嵌合抗原受体及其用途
KR20210150432A (ko) 인간화 항-dll3 키메라 항원 수용체 및 이의 용도
TW202432828A (zh) Ａｄｇｒｅ２嵌合受體ｎｋ細胞組成物及使用方法
US20240207407A1 (en) Egfrviii binding proteins
JP2025529903A (ja) デルタ様リガンド３（ｄｌｌ３）に特異的な抗体およびキメラ抗原受容体
WO2023177974A2 (en) Anti-mesothelin antibodies and uses thereof
JP2024513485A (ja) 免疫細胞活性を制御する方法
WO2026061484A1 (en) NKp80-BINDING PROTEINS AND USES THEREOF
TW202305137A (zh) 靶向白蛋白的嵌合抗原受體及其使用方法
WO2025072871A2 (en) ANTI-SIRPα ANTIBODY COMPOSITIONS AND USES THEREOF
JP2025530110A (ja) 二重特異性ポリペプチド及びその使用
JP2026513651A (ja) Ａｄｇｒｅ２キメラ受容体ｎｋ細胞組成物及び使用方法
WO2024206549A2 (en) Engineered immune cells and use thereof
CN117750963A (zh) 新的细胞疗法系统
AU2024306505A1 (en) Molecules and methods for activating car t cells
CN113528560A (zh) 靶向白蛋白的嵌合抗原受体及其使用方法
HK40120953A (zh) 抗间皮素抗体及其用途
HK40056378B (zh) 人源化抗claudin18.2嵌合抗原受体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250724

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250724